Bellicum Pharma (BLCM) Tops Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Bellicum Pharma (BLCM) Tops Q4 EPS by 8c

Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

March 13, 2018 4:01 PM EDT

Recruitment completed in European BP-004 registration trial of BPX-501 and rimiducid

Positive BPX-501 interim results reported in AML and primary immunodeficiencies

GoCAR-T candidate BPX-601 targeting PSCA in pancreatic cancer shows early promise with robust cell expansion in first patient dosed

Management to host conference call and webcast today at 5 p.m. Eastern

HOUSTON, March 13, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today... More